Echinacoside protects against 6-hydroxydopamine-induced mitochondrial dysfunction and inflammatory responses in PC12 cells via reducing ROS production

Evidence-based Complementary and Alternative Medicine

Volumn 2015, Issue , 2015, Pages

  Wang, Yue Hua ^a   Xuan, Zhao Hong ^b   Tian, Shuo ^a   Du, Guan Hua ^a  

^a INSTITUTE OF MATERIA MEDICA   (China)

^b SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ECHINACOSIDE; INTERLEUKIN 1BETA; INTERLEUKIN 6; OXIDOPAMINE; REACTIVE OXYGEN METABOLITE;

ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; CELL STRUCTURE; CELL VIABILITY; CONTROLLED STUDY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; INFLAMMATION; MITOCHONDRIAL MEMBRANE POTENTIAL; NEUROPROTECTION; NEUROTOXICITY; OXIDATION REDUCTION REACTION; PC12 CELL LINE; PRIORITY JOURNAL;

EID: 84924254935     PISSN: 1741427X     EISSN: 17414288     Source Type: Journal    
DOI: 10.1155/2015/189239     Document Type: Article

References (39)

1. C. Noelker, M. Bacher, P. Gocke et al. , "The flavanoide caffeic acid phenethyl ester blocks 6-hydroxydopamine-induced neurotoxicity," Neuroscience Letters, vol. 383, no. 1-2, pp. 39-43, 2005.
2. D. Blum, S. Torch, N. Lambeng et al. , "Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease," Progress in Neurobiology, vol. 65, no. 2, pp. 135-172, 2001.
3. R. H. Swerdlow, "The neurodegenerative mitochondriopathies," Journal of Alzheimer's Disease, vol. 17, no. 4, pp. 737-751, 2009.
4. M. Karbowski, "Mitochondria on guard: role of mitochondrial fusion and fission in the regulation of apoptosis," Advances in Experimental Medicine and Biology, vol. 687, pp. 131-142, 2010.
5. Y. T. Shih, I. J. Chen, Y. C. Wu, and Y. C. Lo, "San-Huang-Xie-Xin-Tang protects against activated microglia-and 6-OHDAinduced toxicity in neuronal SH-SY5Y cells," Evidence Based Complementory and Alternative Medicine, vol. 2011, Article ID 429384, 11 pages, 2011.
6. B. S. Jeon, V. Jackson-Lewis, and R. E. Burke, "6-Hydroxydopamine lesion of the rat Substantia nigra: time course and morphology of cell death," Neurodegeneration, vol. 4, no. 2, pp. 131-137, 1995.
7. G. Nie, Y. Cao, and B. Zhao, "Protective effects of green tea polyphenols and their major component, (?)-epigallocatechin-3-gallate (EGCG), on 6-hydroxydopamine-induced apoptosis in PC12 cells," Redox Report, vol. 7, no. 3, pp. 171-177, 2002.
8. G. Nie, C. Jin, Y. Cao, S. Shen, and B. Zhao, "Distinct effects of tea catechins on 6-hydroxydopamine-induced apoptosis in PC12 cells," Archives of Biochemistry and Biophysics, vol. 397, no. 1, pp. 84-90, 2002.
9. Y.-H. Wang, H.-T. Yu, X.-P. Pu, and G.-H. Du, "Baicalein prevents 6-hydroxydopamine-induced mitochondrial dysfunction in SH-SY5Y cells via inhibition of mitochondrial oxidation and up-regulation of DJ-1 protein expression,"Molecules, vol. 18, no. 12, pp. 14726-14738, 2013.
10. Y.-H. Wang, Z.-H. Xuan, S. Tian, G.-R. He, and G.-H. Du, "Myricitrin attenuates 6-hydroxydopamine-induced mitochondrial damage and apoptosis in PC12 cells via inhibition of mitochondrial oxidation," Journal of Functional Foods, vol. 5, no. 1, pp. 337-345, 2013.
11. B. Fornstedt, E. Rosengren, and A. Carlsson, "Occurrence and distribution of 5-S-cysteinyl derivatives of dopamine, dopa and dopac in the brains of eight mammalian species," Neuropharmacology, vol. 25, no. 4, pp. 451-454, 1986.
12. L. Lei, F. Q. Yang, T. Y. Zhang, P. Tu, L. Wu, and Y. Ito, "Preparative isolation and purification of acteoside and 2-acetyl acteoside from Cistanches salsa (C. A. Mey.) G. Beck by high-speed counter-current chromatography," Journal of Chromatography A, vol. 912, no. 1, pp. 181-185, 2001.
13. W. He, T. Fang, and P. Tu, "Research progress on pharmacological activities of echinacoside," Zhongguo Zhong Yao Za Zhi, vol. 34, no. 4, pp. 476-479, 2009.
14. Y. Li, Y.-Y. Song, and H.-Q. Zhang, "Effect of echinacoside on immune function and mitochondrial DNA relative content of aging mice," Chinese Pharmacological Bulletin, vol. 26, no. 6, pp. 810-813, 2010.
15. G. Muteliefu, L. Li, andP. F. Tu, "Studyonmolecularmechanism of echinacoside for against aging," Acta Biophysica Sinica, vol. 20, no. 3, pp. 184-187, 2004.
16. X. Geng, X. Tian, P. Tu, and X. Pu, "Neuroprotective effects of echinacoside in themouse MPTP model of Parkinson's disease," European Journal of Pharmacology, vol. 564, no. 1-3, pp. 66-74, 2007.
17. H. Chen, F. C. Jing, C. L. Li, P. F. Tu, Q. S. Zheng, and Z. H. Wang, "Echinacoside prevents the striatal extracellular levels of monoamine neurotransmitters from diminution in 6-hydroxydopamine lesion rats," Journal of Ethnopharmacology, vol. 114, no. 3, pp. 285-289, 2007.
18. M. Deng, J. Y. Zhao, P. F. Tu, Y. Jiang, Z. B. Li, and Y. H. Wang, "Echinacoside rescues the SHSY5Y neuronal cells from TNFalpha-induced apoptosis," European Journal of Pharmacology, vol. 505, no. 1-3, pp. 11-18, 2004.
19. Y.-H. Wang and G.-H. Du, "Ginsenoside Rg1 inhibits -secretase activity in vitro and protects against A-induced cytotoxicity in PC12 cells," Journal of Asian Natural Products Research, vol. 11, no. 7, pp. 604-612, 2009.
20. M. A. Tirmenstein, C. X. Hu, M. S. Scicchitano et al. , "Effects of 6-hydroxydopamine on mitochondrial function and glutathione status in SH-SY5Y human neuroblastoma cells," Toxicology in Vitro, vol. 19, no. 4, pp. 471-479, 2005.
21. Y.-H. Wang, H.-T. Yu, Y.-P. Han, X.-P. Pu, and G.-H. Du, "Protocatechualdehyde prevents methylglyoxal-induced mitochondrial dysfunction and AGEs-RAGE axis activation in human lens epithelial cells," European Journal of Pharmacology, vol. 738, no. 6, pp. 374-383, 2014.
22. Y.-H. Wang, H.-T. Yu, X.-P. Pu, and G.-H. Du, "Myricitrin alleviates methylglyoxal-induced mitochondrial dysfunction and AGEs/RAGE/NF-B pathway activation in SH-SY5Y cells," Journal of Molecular Neuroscience, vol. 53, no. 4, pp. 562-570, 2014.
23. R. A. Eliseev, J. Malecki, T. Lester, Y. Zhang, J. Humphrey, and T. E. Gunter, "Cyclophilin D interacts with Bcl2 and exerts an anti-apoptotic effect,"The Journal of Biological Chemistry, vol. 284, no. 15, pp. 9692-9699, 2009.
24. C. Hermann, A. M. Zeiher, and S. Dimmeler, "Shear stress inhibits H2O2-induced apoptosis of human endothelial cells by modulation of the glutathione redox cycle and nitric oxide synthase," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 17, no. 12, pp. 3588-3592, 1997.
25. D.-S. Hwang, H. G. Kim,H.-J. Kwon et al. , "Dangguijakyak-san, a medicinal herbal formula, protects dopaminergic neurons from 6-hydroxydopamine-induced neurotoxicity," Journal of Ethnopharmacology, vol. 133, no. 2, pp. 934-939, 2011.
26. A. H. V. Schapira, "Mitochondrial dysfunction in neurodegenerative disorders," Biochimica et Biophysica Acta: Bioenergetics, vol. 1366, no. 1-2, pp. 225-233, 1998.
27. M. F. Beal, "Parkinson's disease: a model dilemma," Nature, vol. 466, no. 7310, pp. S8-S10, 2010.
28. B. Ferger, C. Themann, S. Rose, B. Halliwell, and P. Jenner, "6-Hydroxydopamine increases the hydroxylation and nitration of phenylalanine in vivo: implication of peroxynitrite formation," Journal of Neurochemistry, vol. 78, no. 3, pp. 509-514, 2001.
29. E. Méndez-Álvarez, R. Soto-Otero, A. Hermida-Ameijeiras, M. E. López-Martń, and J. L. Labandeira-Garć?a, "Effect of iron and manganese on hydroxyl radical production by 6-hydroxydopamine: mediation of antioxidants," Free Radical Biology and Medicine, vol. 31, no. 8, pp. 986-998, 2001.
30. Z. Ma, X. Wei, C. Fontanilla et al. , "Caffeic acid phenethyl ester blocks free radical generation and 6-hydroxydopamineinduced neurotoxicity," Life Sciences, vol. 79, no. 13, pp. 1307-1311, 2006.
31. J. C. Bensadoun, O. Mirochnitchenko, M. Inouye, P. Aebischer, and A. D. Zurn, "Attenuation of 6-OHDA-induced neurotoxicity in glutathione peroxidase transgenic mice," European Journal of Neuroscience, vol. 10, no. 10, pp. 3231-3236, 1998.
32. B. Ferger, P. Teismann, and J. Mierau, "The dopamine agonist pramipexole scavenges hydroxyl free radicals induced by striatal application of 6-hydroxydopamine in rats: an in vivo microdialysis study," Brain Research, vol. 883, no. 2, pp. 216-223, 2000.
33. K. Prokai-Tatrai and L. Prokai, "Impact of metabolism on the safety of estrogen therapy," Annals of the New York Academy of Sciences, vol. 1052, no. 6, pp. 243-257, 2005.
34. K. Sas, H. Robotka, J. Toldi, and L. Vécsei, "Mitochondria, metabolic disturbances, oxidative stress and the kynurenine system, with focus on neurodegenerative disorders," Journal of the Neurological Sciences, vol. 257, no. 1-2, pp. 221-239, 2007.
35. M. Nakai, A. Mori, A. Watanabe, and Y. Mitsumoto, "1-Methyl-4-phenylpyridinium (MPP+) decreases mitochondrial oxidation-reduction (REDOX) activity and membrane potential () in rat striatum," Experimental Neurology, vol. 179, no. 1, pp. 103-110, 2003.
36. Y. Saito, K. Nishio, Y. Ogawa et al. , "Molecular mechanisms of 6-hydroxydopamine-induced cytotoxicity in PC12 cells: involvement of hydrogen peroxide-dependent and-independent action," Free Radical Biology and Medicine, vol. 42, no. 5, pp. 675-685, 2007.
37. S. Przedborski, "Inflammation and Parkinson's disease pathogenesis. ," Movement Disorders, vol. 25, supplement 1, pp. S55-S57, 2010.
38. C. Barcia, A. F. Barreiro, M. Poza, and M.-T. Herrero, "Parkinson's disease and inflammatory changes," Neurotoxicity Research, vol. 5, no. 6, pp. 411-417, 2003.
39. M. Mogi, M. Harada, T. Kondo et al. , "Interleukin-1, interleukin-6, epidermal growth factor and transforming growth factor- are elevated in the brain from parkinsonian patients," Neuroscience Letters, vol. 180, no. 2, pp. 147-150, 1994.